.jpg "BioLife Solutions (NASDAQ: BLFS)")
Today, a Director at BioLife Solutions (NASDAQ: BLFS), Raymond Cohen, sold shares of BLFS for $101.5K.
Following Raymond Cohen’s last BLFS Sell transaction on February 09, 2017, the stock climbed by 8.9%. This is Cohen’s first Sell trade following 3 Buy transactions.
See today’s analyst top recommended stocks >>
Based on BioLife Solutions’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.81 million and quarterly net profit of $3,482. In comparison, last year the company earned revenue of $2.37 million and had a GAAP net loss of $870.3K. Currently, BioLife Solutions has an average volume of 261.5K. The Company has a Price to Book ratio of 14.4677.
The insider sentiment on BioLife Solutions has been negative according to 30 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Raymond Cohen’s trades have generated a 31.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of portfolio of biopreservation tools for cells, tissues, and organs including proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its products include CryoStor, BloodStor, HypoThermosol FRS, and Cell Thawing Media.
